U.S. and European Union Osteoporosis Drugs Market Size and Share Analysis by Type (Bisphosphonates, RANK Ligand Inhibitors, Parathyroid Hormone Therapy, SERMs), Route of Administration (Injectable, Oral & Spray), Application (Primary Osteoporosis, Secondary Osteoporosis) - Industry Demand Forecast to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Analysis Period

1.4 Market Data Reporting Unit

1.4.1 Value

1.5 Market Size Breakdown by Segment

1.5.1 Market Segmentation by Type

1.5.2 Market Segmentation by Route of Administration

1.5.3 Market Segmentation by Application

1.5.4 Market Segment Analysis of Countries

1.6 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Paid

2.1.2 Unpaid

2.1.3 P&S Intelligence Database

2.2 Primary Research

2.2.1 Breakdown of Primary Research, by Designation

2.2.2 Breakdown of Primary Research, by Company Type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Currency Conversion Rates

2.6 Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Definition of Market Segments

4.1 By Type

4.1.1 Bisphosphonates

4.1.2 RANKL Inhibitors

4.1.3 Parathyroid Hormone Therapy

4.1.4 SERMs

4.1.5 Others

4.2 By Route of Administration

4.2.1 Injectable

4.2.2 Oral & Spray

4.3 By Application

4.3.1 Primary Osteoporosis

4.3.2 Secondary Osteoporosis

Chapter 5. Industry Outlook

5.1 Market Dynamics

5.1.1 Trends

5.1.1.1 Increasing awareness of osteoporosis care

5.1.2 Drivers

5.1.2.1 Rising prevalence of osteoporosis

5.1.2.2 Surging treatment strategies for osteoporosis

5.1.2.3 Increasing osteoporosis clinical trials pipeline

5.1.2.4 Growing geriatric population

5.1.2.5 Rising healthcare expenditure

5.1.3 Impact Analysis of Drivers on Market Forecast

5.1.4 Restraints

5.1.4.1 Growing gap in treatment options

5.1.4.2 Patent expiration of osteoporosis drugs

5.1.5 Impact Analysis of Restraints on Market Forecast

5.2 Impact of COVID-19

5.3 Porter’s Five Forces Analysis

5.3.1 Bargaining Power of Buyers

5.3.2 Bargaining Power of Suppliers

5.3.3 Intensity of Rivalry

5.3.4 Threat of New Entrants

5.3.5 Threat of Substitutes

Chapter 6. Regulatory Framework for Drug Approval

6.1 U.S.

6.2 Europe

6.2.1 Centralized Procedure

6.2.2 Mutual Recognition Procedure

6.2.3 Decentralized Procedure

6.2.4 Nationalized Procedure

6.3 Japan

Chapter 7. Global Market Size and Forecast

7.1 North America, by Country

7.2 Europe, by Region

Chapter 8. U.S. Market Size and Forecast

8.1 Overview

8.2 Market Revenue, by Type (2019–2030)

8.3 Market Revenue, by Route of Administration (2019–2030)

8.4 Market Revenue, by Application (2019–2030)

Chapter 9. European Union Market Size and Forecast

9.1 Overview

9.2 Market Revenue, by Type (2019–2030)

9.3 Market Revenue, by Route of Administration (2019–2030)

9.4 Market Revenue, by Application (2019–2030)

9.5 Market Revenue, by Country (2019–2030)

Chapter 10. Germany Market Size and Forecast

10.1 Overview

10.2 Market Revenue, by Type (2019–2030)

10.3 Market Revenue, by Route of Administration (2019–2030)

10.4 Market Revenue, by Application (2019–2030)

Chapter 11. France Market Size and Forecast

11.1 Overview

11.2 Market Revenue, by Type (2019–2030)

11.3 Market Revenue, by Route of Administration (2019–2030)

11.4 Market Revenue, by Application (2019–2030)

Chapter 12. Italy Market Size and Forecast

12.1 Overview

12.2 Market Revenue, by Type (2019–2030)

12.3 Market Revenue, by Route of Administration (2019–2030)

12.4 Market Revenue, by Application (2019–2030)

Chapter 13. Spain Market Size and Forecast

13.1 Overview

13.2 Market Revenue, by Type (2019–2030)

13.3 Market Revenue, by Route of Administration (2019–2030)

13.4 Market Revenue, by Application (2019–2030)

Chapter 14. Austria Market Size and Forecast

14.1 Overview

14.2 Market Revenue, by Type (2019–2030)

14.3 Market Revenue, by Route of Administration (2019–2030)

14.4 Market Revenue, by Application (2019–2030)

Chapter 15. Belgium Market Size and Forecast

15.1 Overview

15.2 Market Revenue, by Type (2019–2030)

15.3 Market Revenue, by Route of Administration (2019–2030)

15.4 Market Revenue, by Application (2019–2030)

Chapter 16. Netherlands Market Size and Forecast

16.1 Overview

16.2 Market Revenue, by Type (2019–2030)

16.3 Market Revenue, by Route of Administration (2019–2030)

16.4 Market Revenue, by Application (2019–2030)

Chapter 17. Rest of the EU Market Size and Forecast

17.1 Overview

17.2 Market Revenue, by Type (2019–2030)

17.3 Market Revenue, by Route of Administration (2019–2030)

17.4 Market Revenue, by Application (2019–2030)

Chapter 18. Competitive Landscape

18.1 FDA-Approved Drugs for Osteoporosis Treatment and Prevention

18.2 Competitive Benchmarking of Key Players

18.3 Product Benchmarking of Key Players

18.4 Recent Strategic Developments of Key Players

18.4.1 Product Launches

18.4.2 Partnerships

18.4.3 Other Developments

Chapter 19. Company Profiles

19.1 Eli Lilly and Company

19.1.1 Business Overview

19.1.2 Product and Service Offerings

19.1.3 Key Financial Summary

19.2 Amgen Inc.

19.2.1 Business Overview

19.2.2 Product and Service Offerings

19.2.3 Key Financial Summary

19.3 Aurobindo Pharma

19.3.1 Business Overview

19.3.2 Product and Service Offerings

19.3.3 Key Financial Summary

19.4 Sandoz International GmbH

19.4.1 Business Overview

19.4.2 Product and Service Offerings

19.5 Organon & Co.

19.5.1 Business Overview

19.5.2 Product and Service Offerings

19.5.3 Key Financial Summary

19.6 Cipla Ltd.

19.6.1 Business Overview

19.6.2 Product and Service Offerings

19.6.3 Key Financial Summary

19.7 Polpharma API

19.7.1 Business Overview

19.7.2 Product and Service Offerings

19.8 Teva Pharmaceutical Industries Limited

19.8.1 Business Overview

19.8.2 Product and Service Offerings

19.8.3 Key Financial Summary

19.9 Pfizer Inc.

19.9.1 Business Overview

19.9.2 Product and Service Offerings

19.9.3 Key Financial Summary

19.10 EffRx Pharmaceuticals SA

19.10.1 Business Overview

19.10.2 Product and Service Offerings

19.11 Radius Health Inc.

19.11.1 Business Overview

19.11.2 Product and Service Offerings

19.12 Apotex Inc.

19.12.1 Business Overview

19.12.2 Product and Service Offerings

19.13 Viatris Inc.

19.13.1 Business Overview

19.13.2 Product and Service Offerings

19.13.3 Key Financial Summary

19.14 Sun Pharmaceutical Industries Ltd.

19.14.1 Business Overview

19.14.2 Product and Service Offerings

19.14.3 Key Financial Summary

19.15 Theramex HQ UK Limited

19.15.1 Business Overview

19.15.2 Product and Service Offerings

Chapter 20. Appendix

20.1 Abbreviations

20.2 Sources and References

20.3 Related Reports

 

LIST OF TABLES

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 HEALTHCARE EXPENDITURE AS PERCENTAGE OF GDP

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2017–2022)

TABLE 6 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2023–2027)

TABLE 7 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2028–2030)

TABLE 8 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 9 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, $M (2023–2027)

TABLE 10 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, $M (2028–2030)

TABLE 11 EUROPE OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2017–2022)

TABLE 12 EUROPE OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2023–2027)

TABLE 13 EUROPE OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2028–2030)

TABLE 14 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 15 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 16 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 17 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 18 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 19 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 20 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 21 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 22 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 23 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 24 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 25 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 26 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 27 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 28 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 29 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 30 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 31 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 32 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2017–2022)

TABLE 33 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2023–2026)

TABLE 34 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2027–2030)

TABLE 35 KEY OSTEOPOROSIS STATISTICS IN GERMANY

TABLE 36 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 37 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 38 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 39 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 40 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 41 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 42 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 43 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 44 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 45 KEY OSTEOPOROSIS STATISTICS IN FRANCE

TABLE 46 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 47 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 48 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 49 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 50 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 51 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 52 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 53 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 54 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 55 KEY OSTEOPORORSIS STATISTICS IN ITALY

TABLE 56 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 57 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 58 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 59 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 60 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 61 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 62 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 63 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 64 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 65 KEY OSTEOPOROSIS STATISTICS IN SPAIN

TABLE 66 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 67 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 68 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 69 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 70 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 71 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 72 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 73 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 74 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 75 KEY OSTEOPOROSIS STATISTICS IN AUSTRIA

TABLE 76 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 77 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 78 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 79 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 80 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 81 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 82 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 83 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 84 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 85 KEY OSTEOPOROSIS STATISTICS IN BELGIUM

TABLE 86 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 87 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 88 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 89 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 90 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 91 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 92 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 93 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 94 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 95 KEY OSTEOPOROSIS STATISTICS IN NETHERLANDS

TABLE 96 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 97 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 98 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 99 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 100 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 101 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 102 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 103 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 104 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 105 KEY OSTEOPOROSIS STATISTICS IN OTHER EU COUNTRIES

TABLE 106 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 107 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 108 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 109 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 110 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 111 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 112 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 113 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 114 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 115 FDA-APPROVED DRUGS FOR OSTEOPOROSIS TREATMENT AND PREVENTION

TABLE 120 COMPETITIVE BENCHMARKING OF KEY PLAYERS (2023)

TABLE 116 PRODUCT BENCHMARKING OF KEY PLAYERS

TABLE 117 ELI LILLY AND COMPANY – AT A GLANCE

TABLE 118 ELI LILLY AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 119 AMGEN INC. – AT A GLANCE

TABLE 120 AMGEN INC. – KEY FINANCIAL SUMMARY

TABLE 121 AUROBINDO PHARMA – AT A GLANCE

TABLE 122 AUROBINDO PHARMA – KEY FINANCIAL SUMMARY

TABLE 123 SANDOZ INTERNATIONAL GMBH – AT A GLANCE

TABLE 124 ORGANON & CO. – AT A GLANCE

TABLE 125 ORGANON & CO. – KEY FINANCIAL SUMMARY

TABLE 126 CIPLA LTD. – AT A GLANCE

TABLE 127 CIPLA LTD. – KEY FINANCIAL SUMMARY

TABLE 128 POLPHARMA API – AT A GLANCE

TABLE 129 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – AT A GLANCE

TABLE 130 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – KEY FINANCIAL SUMMARY

TABLE 131 PFIZER INC. – AT A GLANCE

TABLE 132 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 133 EFFRX PHARMACEUTICALS SA – AT A GLANCE

TABLE 134 RADIUS HEALTH INC. – AT A GLANCE

TABLE 135 APOTEX INC. – AT A GLANCE

TABLE 136 VIATRIS INC. – AT A GLANCE

TABLE 137 VIATRIS INC. – KEY FINANCIAL SUMMARY

TABLE 138 SUN PHARMACEUTICAL INDUSTRIES LTD. – AT A GLANCE

TABLE 139 SUN PHARMACEUTICAL INDUSTRIES LTD. – KEY FINANCIAL SUMMARY

TABLE 140 THERAMEX HQ UK LIMITED – AT A GLANCE

 

LIST OF FIGURES

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 5 DATA TRIANGULATION APPROACH

FIG 6 U.S. AND EUROPEAN UNION MARKET SUMMARY

FIG 7 BARGAINING POWER OF BUYERS

FIG 8 BARGAINING POWER OF SUPPLIERS

FIG 9 INTENSITY OF RIVALRY

FIG 10 THREAT OF NEW ENTRANTS

FIG 11 THREAT OF SUBSTITUTES

FIG 12 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIAL STAGES)

FIG 13 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)

FIG 14 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU

FIG 15 MARKETING AUTHORIZATION PROCEDURES IN EU

FIG 16 CENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 17 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 18 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN

FIG 19 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2019–2030)

FIG 20 U.S. OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 21 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 22 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 23 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 24 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 25 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 26 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 27 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 28 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2019–2030)

FIG 29 GERMANY OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 30 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 31 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 32 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 33 FRANCE OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 34 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 35 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 36 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 37 ITALY OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 38 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 39 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 40 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 41 SPAIN OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 42 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 43 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 44 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 45 AUSTRIA OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 46 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 47 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 48 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 49 BELGIUM OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 50 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 51 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 52 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 53 NETHERLANDS OSTEOPOROSIS DRUGS MARKET SNAPSHOT

FIG 54 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 55 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 56 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 57 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2030)

FIG 58 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 59 REST OF EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2019–2030)

FIG 60 ELI LILLY AND COMPANY – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2023)

FIG 61 AMGEN INC. – REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2023)

FIG 62 AUROBINDO PHARMA – REVENUE SPLIT BY SEGMENT (2023)

FIG 63 ORGANON & CO. – REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2023)

FIG 64 CIPLA LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 65 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 66 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 67 VIATRIS INC. – REVENUE SPLIT BY THERAPY AND GEOGRAPHY (2023)

FIG 68 SUN PHARMACEUTICAL INDUSTRIES LTD. – REVENUE SPLIT BY GEOGRAPHY (2023)